The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib

Digestive and Liver Disease

Volumn 45, Issue 5, 2013, Pages 408-413

  Wörns, Marcus A ^a   Koch, Sandra ^a   Niederle, Ina M ^a   Marquardt, Jens U ^a   Nguyen Tat, Marc ^a   Gamstätter, Thomas ^a   Schuchmann, Marcus ^a   Schulze Bergkamen, Henning ^b   Galle, Peter R ^a   Weinmann, Arndt ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Advanced liver cancer; Baseline factors; Prognosis; Targeted therapy

Indexed keywords

SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALCOHOL CONSUMPTION; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD PUGH SCORE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876716745     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.10.010     Document Type: Article

References (41)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011, 61(2):69-90.
2. Alazawi W., Cunningham M., Dearden J., et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Alimentary Pharmacology and Therapeutics 2010, 32(3):344-355.
3. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379(9822):1245-1255.
4. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008, 359(4):378-390.
5. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology 2009, 10(1):25-34.
6. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53(3):1020-1022.
7. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 2012, 56(4):908-943.
8. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 2004, 64(19):7099-7109.
9. Worns M.A., Galle P.R. Future perspectives in hepatocellular carcinoma. Digestive and Liver Disease 2010, 42(Suppl 3):S302-S309.
10. Worns M.A., Galle P.R. Novel inhibitors in development for hepatocellular carcinoma. Expert Opinion on Investigational Drugs 2010, 19(5):615-629.
11. Cheng A.L., Guan Z., Chen Z., et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial. European Journal of Cancer 2012, 48(10):1452-1465.
12. Raoul J.L., Bruix J., Greten T.F., et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. Journal of Hepatology 2012, 56(5):1080-1088.
13. Bruix J., Raoul J.L., Sherman M., et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. Journal of Hepatology 2012, 57(4):821-829.
14. Yau T., Chan P., Ng K.K., et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009, 115(2):428-436.
15. Worns M.A., Weinmann A., Pfingst K., et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. Journal of Clinical Gastroenterology 2009, 43(5):489-495.
16. Pinter M., Sieghart W., Graziadei I., et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009, 14(1):70-76.
17. Ozenne V., Paradis V., Pernot S., et al. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology & Hepatology 2010, 22(9):1106-1110.
18. Hollebecque A., Cattan S., Romano O., et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Alimentary Pharmacology and Therapeutics 2011, 34(10):1193-1201.
19. Song T., Zhang W., Wu Q., et al. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. European Journal of Gastroenterology and Hepatology 2011, 23(12):1233-1238.
20. Baek K.K., Kim J.H., Uhm J.E., et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology 2011, 80(3-4):167-174.
21. Kim J.E., Ryoo B.Y., Ryu M.H., et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemotherapy and Pharmacology 2011, 68(5):1285-1290.
22. Marrero J.A., Lencioni R., Kudo M., et al. Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1500 patients: Clinical findings in patients with liver dysfunction. Journal of Clinical Oncology 2011, 29(suppl). [abstr 4001].
23. Pinter M., Sieghart W., Hucke F., et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Alimentary Pharmacology and Therapeutics 2011, 34(8):949-959.
24. Chiu J., Tang Y.F., Yao T.J., et al. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer 2012.
25. Daniele B., Di Maio M. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?. Journal of Clinical Gastroenterology 2009, 43(5):389-390.
26. Di Maio M., Daniele B., Perrone F. Targeted therapies: role of sorafenib in HCC patients with compromised liver function. Nature Reviews Clinical Oncology 2009, 6(9):505-506.
27. Abou-Alfa G.K., Amadori D., Santoro A., et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointestinal Cancer Research 2011, 4(2):40-44.
28. Lencioni R., Kudo M., Ye S.L., et al. First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study. International Journal of Clinical Practice 2012, 66(7):675-683.
29. Grenne F.L., Page D.L., Fleming I.D., et al. Liver including intrahepatic bile ducts. American Joint Committee on Cancer Staging Manuel 2002, Springer, Chicago. 6th ed.
30. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in Liver Disease 1999, 19(3):329-338.
31. Worns M.A., Schuchmann M., Duber C., et al. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology 2010, 79(1-2):85-92.
32. Weinmann A., Niederle I.M., Koch S., et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Digestive and Liver Disease 2012, 44(5):432-437.
33. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56(4):918-928.
34. A., new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP), investigators. Hepatology 1998, 28(3):751-755.
35. Kudo M., Chung H., Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). Journal of Gastroenterology 2003, 38(3):207-215.
36. Marrero J.A., Fontana R.J., Barrat A., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41(4):707-716.
37. Tandon P., Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver International 2009, 29(4):502-510.
38. Uka K., Aikata H., Takaki S., et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World Journal of Gastroenterology 2007, 13(3):414-420.
39. Lee H.S. Management of patients with hepatocellular carcinoma and extrahepatic metastasis. Digestive Diseases 2011, 29(3):333-338.
40. Uchino K., Tateishi R., Shiina S., et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 2011, 117(19):4475-4483.
41. Pinter M., Hucke F., Graziadei I., et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 2012, 263(2):590-599.